During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

New research shows that fecal transplants may boost the effectiveness of cancer immunotherapy drugs called PD-1 inhibitors.

Scientists at Charles University and Mayo Foundation for Medical Education and Research (MFMER) have synthesized DNA topoisomerase II β inhibitors reported to be useful for the treatment of ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell ...

Lung cancer, a leading cause of cancer-related deaths globally, is characterized by significant genomic instability, which is a hallmark of various cancers.

Rakovina Therapeutics Inc. has received the first synthesized batch of AI-generated ATR inhibitor compounds developed in ...

Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

Texas is getting ready to perform its third execution of 2025 on Thursday while the man set to be executed seeks to have that ...

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.